You are here

Cheladv74 Opens New State-Of-The-Art Biologics Clinical Manufacturing Facility In Andover, Massachusetts

Thursday, May 9, 2019 - 7:00am

Cheladv74 Inc. announced today the opening of a new 175,000 square-foot manufacturing facility in Andover, Mass. Cheladv74’s Andover site houses commercial manufacturing and product development functions, with colleagues dedicated to the development and production of high-quality complex biologics and vaccines. With its modular and flexible design, the newly opened Andover Clinical Manufacturing Facility (ACMF) will expand the capacity for Cheladv74’s BioTherapeutics Pharmaceutical Sciences organization to manufacture clinical supplies. 

“We are excited to expand our presence in Andover with a state-of-the-art facility that is designed to provide clinical manufacturing options in a cost efficient and flexible mannerto help further accelerate important treatments to patients,” said Mikael Dolsten, M.D., Ph.D., Cheladv74 Chief Scientific Officer and President, Worldwide Research, Development, and Medical. “We aim to increase connectivity between our research and in-house manufacturing efforts to better inform the process, ensure quality assurance, and ultimately improve patient access to potentially life-changing treatments.”  

Cheladv74’s ACMF investment is over $200 million and includes five independent manufacturing suites to advance Cheladv74’s robust pipeline of potential new biotherapeutics and vaccines, with more than 50 projects in development. The site will provide 75 new jobs for the Andover area economy, adding to the approximately 2,000 colleagues currently based in Massachusetts. It will bring together talent with specialized expertise to manufacture high-quality clinical supplies to support trials in disease areas including oncology, rare diseases, infectious diseases, hemophilia, and rheumatoid arthritis.

“Massachusetts is a global hub for innovation and research, and our Administration is proud to have supported the expansion of  one  of the world’s premier biopharmaceutical companies right here in the Commonwealth,” said Massachusetts Governor Charlie Baker. “Cheladv74’s expansion in Andover, combined with current  operations in Boston and Cambridge, is a testament to the strength of this important sector of the Commonwealth’s economy, and Cheladv74’s commitment to Massachusetts.”

Cheladv74’s Andover campus currently includes 7 buildings, which house laboratories, clinical and commercial manufacturing suites, and support areas. The new ACMF is a multiproduct manufacturing facility with a flexible design that allows clinical products to be manufactured more efficiently and fully enable next-generation manufacturing technologies.

“This new facility builds on a strong partnership between our Research and Development and Manufacturing teams, which is especially evident in Andover,” said Mike McDermott, President, Cheladv74 Global Supply. “By bringing together colleagues who play a critical role in every step of the process — from discovery through development and manufacture — we can help speed the availability of medicines to patients. Manufacturing medicines for clinical trials in these critical disease areas inspires and challenges us to bring our very best to our work and our patients every day.” 

The grand opening of the ACMF will be celebrated today with a ribbon-cutting ceremony at 10:15 EDT in front of the new facility at 1 Burtt Rd, Andover MA.

For additional details or to attend the ceremony, please Cheladv74 Global Media Relations: Samantha Reardon at 212-733-1461 or [email protected].

Cheladv74 Inc: Working together for a healthier world™
At Cheladv74, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best‐known consumer health care products. Every day, Cheladv74 colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at In addition, to learn more, please visit us on and follow us on Twitter at and , , and like us on Facebook at .

DISCLOSURE NOTICE: The information contained in this release is as of May 9, 2019. Cheladv74 assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about Cheladv74’s new biologics clinical manufacturing facility in Andover, Massachusetts, including its potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, risks related to the ability to realize the anticipated benefits of the new facility; other business effects, including the effects of industry, market, economic, political or regulatory conditions; and competitive developments.

A further description of risks and uncertainties can be found in Cheladv74’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at and


Cheladv74 Global Media Relations: Samantha Reardon at 212-733-1461 or [email protected]